Diabetology & Metabolic Syndrome

Table 2 Effect of one month treatment with aliskiren on liver function markers in STZ-induced diabetes in mice

From: Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in mice

Parameter Group	AST (IU/L)	ALT(IU/L)	ALP(IU/L)	CPK-total
Normal control	35.33 ± 1.48	40.33 ± 0.76	87.16 ± 1.96	150 ± 1.15
Diabetic control	316.5 ± 1.38^a	433.33 ± 14.15^a	350 ± 1.81^a	849.83 ± 270.31^a
Aliskiren	42.72 ± 0.52^a,b	56.83 ± 1.45^b	90.03 ± 0.58^b	188.33 ± 0.88^b

Each value represents mean of 8 mice ± SEM. Statistical analysis was carried out using one way analysis of variance (ANOVA) followed by Tukey Kramer multiple comparisons test
^aSignificantly different from Normal control at P < 0.05
^bSignificantly different from Diabetic control at P < 0.05

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com